Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice

被引:18
作者
Cao, TM
Lo, B
Ranheim, EA
Grumet, FC
Shizuru, JA
机构
[1] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[3] Ctr Blood, Stanford Med Sch, Histocompatibil Lab, Palo Alto, CA 94304 USA
关键词
histocompatibility antigens; hematopoietic stem cell transplantation;
D O I
10.1073/pnas.2035077100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
MHC typing for human hematopoietic cell transplantation (HCT) from unrelated donors is currently performed by using a combination of serologic and molecular techniques. It has been determined that allelic differences in human MHC molecules, revealed by nucleotide sequencing but not by serologic typing, substantially influence graft rejection and graft-versus-host disease, two serious complications of clinical HCT. We studied transplantation of purif ied hematopoietic stem cells in a series of mouse strains that were matched at the MHC but had different background genes, and we observed striking differences in engraftment resistance and graft-versus-host disease severity, both factors depending on the donor-recipient strain combination. The individual mouse lines studied here were established nearly a century ago, and their MHC types were determined exclusively by serologic techniques. We considered the possibility that serologically silent MHC polymorphisms could account for our observations and, therefore, we performed DNA sequencing of the class I and 11 MHC alleles of our mouse strains. At each locus, exact homology was found between serologically MHC-matched strains. Our results likely extend to all serologically MHC-matched mouse strains used in modern research and highlight the profound and variable influence that non-MHC genetic determinants can have in dictating outcome after HCT.
引用
收藏
页码:11571 / 11576
页数:6
相关论文
共 40 条
[1]   Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice [J].
Cetkovic-Cvrlje, M ;
Roers, BA ;
Waurzyniak, B ;
Liu, XP ;
Uckun, FM .
BLOOD, 2001, 98 (05) :1607-1613
[2]   Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide [J].
Choi, EY ;
Christianson, GJ ;
Yoshimura, Y ;
Sproule, TJ ;
Jung, NJ ;
Joyce, S ;
Roopenian, DC .
IMMUNITY, 2002, 17 (05) :593-603
[3]   Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells [J].
Christensen, JL ;
Weissman, IL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) :14541-14546
[4]  
DIETRICH W, 1992, GENETICS, V131, P423
[5]  
Furth J, 1978, ORIGINS INBRED MICE, P69
[6]   CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers [J].
Gandy, KL ;
Domen, J ;
Aguila, H ;
Weissman, IL .
IMMUNITY, 1999, 11 (05) :579-590
[7]   Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia [J].
Hill, GR ;
Teshima, T ;
Gerbitz, A ;
Pan, LY ;
Cooke, KR ;
Brinson, YS ;
Crawford, JM ;
Ferrara, JLM .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (04) :459-467
[8]   A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors [J].
Hurley, CK ;
Wade, JA ;
Oudshoorn, M ;
Middleton, D ;
Kukuruga, D ;
Navarrete, C ;
Christiansen, F ;
Hegland, J ;
Ren, EC ;
Andersen, I ;
Cleaver, SA ;
Brautbar, C ;
Raffoux, C .
TISSUE ANTIGENS, 1999, 53 (04) :394-406
[9]  
KAUFMAN CL, 1994, BLOOD, V84, P2436
[10]  
KLEIN J, 1986, NATURAL HIST MAJOR H, P609